Fibromyalgia/Pain

Chronic pain may dramatically raise your blood pressure Widespread chronic pain may stealthily drive up blood pressure, partly through its ties to depression and inflammation. https://t.co/siqtSHXHIW https://t.co/wAwDLkxGxQ

Links:

Dr. John Cush @RheumNow( View Tweet )
Obesity-inflammation axis in PsO & PsA: obesity is assoc w/ less remission& poorer drug responses; possibly from adipokines, biomechanical stress, gut dysbiosis, etc. Notably, weight loss can improve both psoriatic disease course and response to therapy. https://t.co/cZbeu0zfmR https://t.co/EoCTNKk265

Links:

Dr. John Cush @RheumNow( View Tweet )
BASDAI scores elevated in Fibromyalgia - 58 FM pts were surveyed wtih FIQ, SSS, BASDAI. BASDAI was ≥ 4 points in 91.4% of FM (vs 13% controls (p < 0.001). BASDAI correlated w/ the FIQ (pain, fatigue, stiffness) & SSS scores (r = 0.88, p < 0.00). Could BASDAI be used in FM? https://t.co/VF94ru0o3Q
Dr. John Cush @RheumNow( View Tweet )
JAMA review of Peripheral Neuropathy - affects ~ 1% of adults worldwide and may cause sensory, motor, and autonomic Sxs. Diabetes is the most common cause. 1st line Rxs include gabapentin, pregabalin, duloxetine, amitriptyline. (FOR AMA MEMBERS) https://t.co/sof15I1GpU https://t.co/PN0KMeUsGA

Links:

Dr. John Cush @RheumNow( View Tweet )
BP.jpg

Chronic pain may dramatically raise your blood pressure

Science Daily

Widespread chronic pain may stealthily drive up blood pressure, partly through its ties to depression and inflammation.

Read Article
Retrospective analysis of 2614 FM pts in the Italian Fibromyalgia Registry underscores the seasonal changes in FM pain, w/ signif. differences in FM assessment tools WPI p=0.042 & FASmod p=0.037); these changes were only seen in female patients, not males https://t.co/LqXnTgGIMB https://t.co/ihw1yJqKLC

Links:

Dr. John Cush @RheumNow( View Tweet )
RETREAT study was a 12 wk RCT of Tai Chi in 178 knee OA pts Rx w/ online OA info vs same plus free web based tai chi video program. Tai Chi group had signif improved knee pain (−2.7 v -1.2); (−12 v −6.9) & achieved a minimal pain & function (73% v 47%); and Its free! https://t.co/WLzQ9YHrcu
Dr. John Cush @RheumNow( View Tweet )
Weight Loss as a Therapeutic Goal in PsA PsA is a complex inflammatory disease often complicated by obesity, which not only worsens disease activity but also impairs treatment response. At #ACR25, 3 compelling studies spanning pharmacologic, lifestyle, and longitudinal https://t.co/Q6IFGn5zCI
Dr. John Cush @RheumNow( View Tweet )
What happens if you have #axSpA & concomitant #FM? Pts with both have less TNFi retention, -residual pain may lead to d/c Rx. Need to determine if axSpA pt has #fibromyalgia as there may not be objective findings if no peripheral arthritis in axSpA. #ACR25 @RheumNow abst#534

Janet Pope @Janetbirdope( View Tweet )

In a PsA cohort (n=1291), higher BMI was independently linked to lower odds of achieving MDA—especially in TNFi-treated patients. Impact was strongest in pain, skin, enthesitis, and PRO domains, not swollen joints. Each unit increase in BMI reduced MDA odds by 4–7%. Highlights https://t.co/TxO3HP51uk

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Abstract 2687: GLP-1 RA in PsA In combined Toronto + NYU cohort, GLP-1 RA significantly associated with reduced: - Weight, CRP, and pain scores - Each 1% reduction in body weight associated w/ TJC, DAPSA, EQ-5D (QoL), LDL, Systolic BP @RheumNow #ACR25 https://t.co/30lPDkALKs

Links:

Akhil Sood MD, MS @AkhilSoodMD( View Tweet )
#ACR25 Clinical Preview by Prof Coates for use now: GLP-1 agonist & Diet Abstr#813 GIP/GLP-1 improved MSK pain Abstr#849 GLP-1 reduced risk of #MACE in PsA Abstr#2690 RCT = the degree of weight loss regardless specific dietary strategy determined benefit in PsA @RheumNow https://t.co/4jB0fFHosC

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Disease activity associated with symtomatic knee OA and increased with increased KL grades Abst#2625 #ACR25 @RheumNow https://t.co/uCrdnVXk0J

Links:

Bella Mehta @bella_mehta( View Tweet )
Perhaps it was my ignorance, but a FDA-approved therapy for fibromyalgia was not on my 2025 bingo card. We’re not exactly overwhelmed with proven options for FM, the unmet need is so great, so the more, the better. #ACR25 FDA session @RheumNow https://t.co/wwWijl3IyW

Links:

David Liew @drdavidliew( View Tweet )
Hindosh et al. Semaglutide associated with reduced synovitis, joint pain and swelling, in RA. @RheumNow #ACR25 Abstr#2286 https://t.co/6Xs4um5l32

Links:

Richard Conway @RichardPAConway( View Tweet )
Gender differences in p/axSpA in Turkiye from ASAS-PerSpA: Males - early onset IBP (<45yrs); sacroiliitis on CR, HLA-B27+ (vs. females) Females - peripheral dse, enthesitis, Pso, dactylitis; ⬆️dse activity, FM (vs. males) Individualize & optimize tx. #ACR25 @RheumNow Abs2322 https://t.co/vcisNguJLB

Links:

sheila @RHEUMarampa( View Tweet )
“I never thought I’d live to old age with MCTD, now I plan for it.” This patient’s journey highlights the power of evolving therapies, resilience, and lifestyle adaptation to age well with chronic autoimmune disease. Patient perspectives abstract #PP04 @rheumnow #ACR25

Jiha Lee @JihaRheum( View Tweet )

GLP-1 in Knee Osteoarthritis https://t.co/SxyVEAK1CZ @bella_mehta Discusses role of GLP1 in OA and possible mechanisms of effectiveness ? weight reduction ? or doses it have anti-inflammatory -anti-fibrotic role ? @RheumNow #ACR25

Links:

Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )

A largely understudied area: Impact of peri-menopause in PsA Toronto Cohort 473pts, HRT 1.5% Peri menopause = increase DAPSA, TJC, SJC, FACIT-fatigue, HAQ compared to pre- and post-menopause No association w/ BMI, but with fatigue Less impact when education level increases https://t.co/bSuGxZCbGn

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
Functional MRI studies have been out there for a while, but mechanisms and significance underlying fMRI findings are unclear fMRI study in 38 active PsA pts w/ significant fatigue Altered functional connectivity between posterior insula to cerebellum & superior frontal gyrus https://t.co/3s9CJUg2uN

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
Abstract 1421: PsA and 'Brain Fog' Pts w/ #PsA who did not achieve Minimal Disease Activity (MDA) had higher odds of subjective cognitive decline vs those with MDA 🔹 Fatigue, and to a lesser extent depression/anxiety, ↓ this associated risk @RheumNow #ACR25 https://t.co/RohwKJZDzp

Links:

Akhil Sood MD, MS @AkhilSoodMD( View Tweet )
I wouldn't sleep on this. 😴💤 Abstract 1413: In a PsA cohort, restless leg syndrome was linked to: 🔹 ↑ disease activity (polyarthritis, swollen joints, DAPSA) 🔹 Worse physical function (↑ HAQ) 🔹 Fatigue, anxiety, depression, & poorer sleep quality @RheumNow #ACR25

Akhil Sood MD, MS @AkhilSoodMD( View Tweet )

X-sectional study by Dr Toledano et al showed that 20% (46/230) PsA pts had restless leg syndrome (RDS). Pts w/ RDS: - Polyarthritis ⬆️ Swollen jts ⬆️ Fatigue, anxiety, depression ⬆️ Dse activity Poor sleep quality Polyarthritis & Pso: assocd w/ RDS #ACR25 @RheumNow Abs1413 https://t.co/8Ds3TgLjs1

Links:

sheila @RHEUMarampa( View Tweet )
Rural RA care looks different but not less intensive: DMARD and GC use matched urban rates, yet rural pts often managed by PCPs had twice the opioid use. ACR's Rheum for Primary Care resource can help address access gap and improve RA care @RheumNow #ACR25 Abstract#1025

Jiha Lee @JihaRheum( View Tweet )

A post-hoc analysis from the ReFlaP study showed that there was a significant correlation between PsAID12 & HAQ scores MDA-PsAIDrem (SN 82.6% SP97.1%) and MDA-PsAIDlow (SN 90.7% SP 91.2%) Potential alternative for HAQ in MDA criteria? #ACR25 @RheumNow Abs1411 https://t.co/QAxKsuhtDq

Links:

sheila @RHEUMarampa( View Tweet )

Recent Blogs

From DNA to PGA

David Pisetsky, MD, PhD
dna
I have been investigating the mechanisms of antinuclear antibody (ANA) expression in SLE since 1978. In this pursuit, I have followed the advice of my first division chief, Dr. Ralph Snyderman, a great academician.  Ralph told me to identify a research focus and make it mine. I think I have done reasonably well in my mission so you can imagine my surprise (and excitement) when, for the Lupus 2025 meeting in Toronto, I was asked to conduct a Meet the Professor session on the Type 1 & 2 model for SLE. Read Post

From the Archives: Rheumatology Dead Word Cemetery

Jack Cush, MD
CTD.jpg
I recently heard of a secondary school assignment wherein students were challenged to “bury” a word that was no longer useful or appropriate. Their exercise has now evolved into an unofficial RheumNow task force to retire diagnostic terms that have grown into misuse in rheumatology and medicine. How did we decide which words should perish? And by what criteria? Who has the final say? Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×